Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups
of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients
(nodular, diffuse large cell, mantle cell plus others). Oral bid dosing with highest
tolerable dose until toxicity, progression, or withdrawal